Zealand Pharma A/S (ZEAL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZEAL Stock Summary
- Of note is the ratio of Zealand Pharma A's sales and general administrative expense to its total operating expenses; merely 0.47% of US stocks have a lower such ratio.
- For ZEAL, its debt to operating expenses ratio is greater than that reported by only 0.52% of US equities we're observing.
- With a year-over-year growth in debt of -100%, Zealand Pharma A's debt growth rate surpasses only 0% of about US stocks.
- Stocks that are quantitatively similar to ZEAL, based on their financial statements, market capitalization, and price volatility, are CGAU, LOV, BTEGF, CPG, and HTLD.
- ZEAL's SEC filings can be seen here. And to visit Zealand Pharma A's official web site, go to www.zealandpharma.com.
ZEAL Stock Price Chart Interactive Chart >
ZEAL Price/Volume Stats
| Current price | $16.20 | 52-week high | $34.30 |
| Prev. close | $18.13 | 52-week low | $9.93 |
| Day low | $15.55 | Volume | 4,798 |
| Day high | $16.45 | Avg. volume | 5,503 |
| 50-day MA | $14.79 | Dividend yield | N/A |
| 200-day MA | $19.09 | Market Cap | 753.74M |
Zealand Pharma A/S (ZEAL) Company Bio
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company was founded in 1997 and is based in Copenhagen, Denmark.
Latest ZEAL News From Around the Web
Below are the latest news stories about Zealand Pharma A that investors may wish to consider to help them evaluate ZEAL as an investment opportunity.
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022Company announcement – No. 5 / 2022 Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022 Copenhagen, DK and Boston, MA, February 25, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: Th |
Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)Company announcement – No. 4 / 2022 Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI) Top-line results expected in the second quarter of 2022Pending positive results, Zealand intends to file for marketing approval with the US Food and Drug Administration Copenhagen, DK and Boston, MA, U.S. February 15, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and |
Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome StudyZealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome. |
Needham Thinks Zealand Pharma’s Stock is Going to RecoverIn a report released today, Joseph Stringer from Needham maintained a Buy rating on Zealand Pharma (ZEAL – Research Report), with a price target of $42.00. The company's shares closed last Thursday at $21.18, close to its 52-week low of $19.33. According to TipRanks.com, Stringer has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -23.4% and a 19.8% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Apellis Pharmaceuticals, and Phathom Pharmaceuticals. Zealand Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $42.00, a 98.5% upside from current levels. |
Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel SyndromeCompany announcement – No. 3 / 2022 Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Full trial results of EASE-SBS 1 expected in the third quarter of 2022Pending positive pivotal data, Zealand intends to file for marketing approval with the U.S. Food and Drug Administration Copenhagen, DK and Boston, MA, U.S. January 20, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the |
ZEAL Price Returns
| 1-mo | 7.71% |
| 3-mo | 61.19% |
| 6-mo | -5.54% |
| 1-year | -39.84% |
| 3-year | -25.52% |
| 5-year | -9.45% |
| YTD | -24.09% |
| 2021 | -40.62% |
| 2020 | 8.25% |
| 2019 | 185.96% |
| 2018 | -14.63% |
| 2017 | N/A |
Continue Researching ZEAL
Want to do more research on Zealand Pharma A's stock and its price? Try the links below:Zealand Pharma A (ZEAL) Stock Price | Nasdaq
Zealand Pharma A (ZEAL) Stock Quote, History and News - Yahoo Finance
Zealand Pharma A (ZEAL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...